相关实验视频
Updated: May 11, 2026
10:00
Measurement of Lifespan in Drosophila melanogaster
Published on: January 7, 2013
34.1K
简要报告:没有创造平等:通过KRAS突变亚型的生存差异,以免疫疗法治疗的NSCLC
Lova Sun1, Yunyun Zhou2, Elizabeth A Handorf2
1Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
JTO clinical and research reports
|January 6, 2025
概括
克拉斯G12V突变表明转移性非小细胞肺癌 (NSCLC) 患者的存活率较差,接受免疫检查点抑制剂 (ICI) 治疗,即使PD-L1表达高. 这一发现表明KRAS G12V瘤可能需要加强治疗策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 免疫治疗是一种免疫疗法.
背景情况:
- 在转移性非小细胞肺癌 (NSCLC) 中,KRAS突变 (KRASm) 亚型的预后和预测价值仍然不清楚.
- 基于免疫检查点抑制剂 (ICI) 的疗法是晚期NSCLC的标准治疗方法,但患者之间的反应有很大差异.
研究的目的:
- 调查KRASm亚型是否对接受基于ICI的治疗的转移性NSCLC患者的存活率产生差异影响.
- 为了分析这些差异,在不同水平的编程死亡连接体1 (PD-L1) 表达.
主要方法:
- 一项全国性的观察性研究包括接受一线ICI治疗 (2016-2021) 的高级非状NSCLC患者.
- 患者已知PD-L1表达和全面的基因组分析,包括KRAS,STK11,KEAP1和TP53.
- 考克斯多变量回归和卡普兰-梅尔方法评估了KRASm亚型 (G12C,G12V,G12D,其他) 与PD-L1亚组内的总生存率 (<1%,1%-49%,≥50%) 之间的关联.
主要成果:
- 在1539名患者中,720人患有KRASm (296 G12C,143 G12V,97 G12D,其他184人).
- 在PD-L1≥50%的小组中,KRAS G12V患者的整体存活率明显较差 (平均存活期=8.2个月),与KRAS野生型 (mOS=13.3个月) 和其他KRASm亚型 (mOS=13.419.9个月) 相比.
- 调整后的分析证实,KRAS G12V与KRAS野生型和其他KRASm亚型相比,死亡风险增加了1.53-1.78倍 (p < 0.05).
结论:
- KRASm亚型不是ICI反应的统一预测因素,即使在高PD-L1表达NSCLC.
- 克拉斯G12V瘤与基于ICI的治疗结果较差,并且可能受益于治疗强化.
- 这些发现强调了特定KRAS突变亚型对于个性化NSCLC治疗策略的重要性.
相关概念视频
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...